Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70260 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Francesco Leo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Objective
The aim of this study is to evaluate the long‐term effectiveness, safety, and achievement of minimal disease activity (MDA) in patients with moderate‐to‐severe AD treated with dupilumab over a 5‐year period.
Methods
A retrospective single‐center cohort study was conducted at the Dermatologic Clinic of the University of Turin, including 583 patients aged ≥ 6 years treated with dupilumab between November 2018 and January 2025. Effectiveness was measured by Eczema Area and Severity Index (EASI), Pruritus‐Numerical Rating Scale (P‐NRS), and Sleep Loss‐Numerical Rating Scale (S‐NRS) scores, Dermatology Life Quality Index (DLQI). MDA was defined as EASI‐90 combined with P‐NRS ≤ 1. Safety and drug survival were also assessed.
Results
Dupilumab treatment resulted in significant and sustained reductions in EASI and symptom scores over 5 years. The proportion of patients achieving MDA increased from 22.0% at 16 weeks to 56.0% at 208 weeks and remained stable at 55.3% through 5 years. Male sex and childhood onset may reduce treatment success, warranting further study. The safety profile was favorable, with low discontinuation rates, and conjunctivitis as the most common adverse event.
Conclusion
Our long‐term real‐world data support the sustained effectiveness and safety of dupilumab in moderate‐to‐severe AD, with over 55% of patients achieving and maintaining MDA at 5 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
ORCID-Profile: Francesco Leo, Pietro Quaglino, Simone Ribero
Zitieren
APA
Leo, F., Mastorino, L., Cangialosi, L., Favre, D., Fiasconaro, C. A., Liao, Y., Goso, F., Siliquini, N., Cavaliere, G., Quaglino, P., Ribero, S., & Ortoncelli, M. (2026). Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab. International Journal of Dermatology. https://doi.org/10.1111/ijd.70260
Vancouver
Leo F, Mastorino L, Cangialosi L, Favre D, Fiasconaro CA, Liao Y, et al. Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab. International Journal of Dermatology. 2026. doi:10.1111/ijd.70260
BibTeX
@article{Leo2026,
author = {Leo, Francesco and Mastorino, Luca and Cangialosi, Luca and Favre, Davide and Fiasconaro, Chiara Anna and Liao, Yingying and Goso, Federico and Siliquini, Niccolò and Cavaliere, Giovanni and Quaglino, Pietro and Ribero, Simone and Ortoncelli, Michela},
title = {Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70260}
}
EUVIMED